Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

about

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

Item

http://www.wikidata.org/entity/Q58748732

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Differential responses of MET ...... itor and neutralizing antibody

@en

Differential responses of MET ...... itor and neutralizing antibody

@nl

type

Item

label

Differential responses of MET ...... itor and neutralizing antibody

@en

Differential responses of MET ...... itor and neutralizing antibody

@nl

prefLabel

Differential responses of MET ...... itor and neutralizing antibody

@en

Differential responses of MET ...... itor and neutralizing antibody

@nl

P1476

Differential responses of MET ...... itor and neutralizing antibody

@en

P2093

Alan Huang

http://www.w3.org/2001/XMLSchema#string

Angela Tam

http://www.w3.org/2001/XMLSchema#string

Ben Staal

http://www.w3.org/2001/XMLSchema#string

Boheng Zhang

http://www.w3.org/2001/XMLSchema#string

George F Vande Woude

http://www.w3.org/2001/XMLSchema#string

Huai-Xiang Hao

http://www.w3.org/2001/XMLSchema#string

Jianqun Kou

http://www.w3.org/2001/XMLSchema#string

Liang Kang

http://www.w3.org/2001/XMLSchema#string

Weizhong Wu

http://www.w3.org/2001/XMLSchema#string

Yuan Qin

http://www.w3.org/2001/XMLSchema#string

P2860

The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

The DNA-damage response in human biology and disease

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

Met, metastasis, motility and more

P2888

s12967-018-1628-y

P304

253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12967-018-1628-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Phillip R Musich

Qian Xie

P577

2018-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106942503

http://www.w3.org/2001/XMLSchema#string

P698

30208970

http://www.w3.org/2001/XMLSchema#string

P932

6134500

http://www.w3.org/2001/XMLSchema#string